Related Experiment Video
Updated: Nov 11, 2025

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling
Kathryn Peebles1, John E Mittler2, Steven M Goodreau3,4
1Department of Epidemiology, University of Washington, Seattle, WA, USA.
Behavioral risk compensation after HIV vaccination may accelerate viral adaptation, potentially reducing vaccine effectiveness and increasing HIV prevalence over time. This highlights the complex interplay between vaccines, behavior, and pathogen evolution.
Area of Science:
- Epidemiology
- Immunology
- Virology
Background:
- Pathogen evolution can reduce vaccine effectiveness.
- HIV (Human Immunodeficiency Virus) adaptation poses a significant challenge for vaccine development.
- Behavioral risk compensation is a potential factor influencing vaccine outcomes.
Purpose of the Study:
- To model the impact of risk compensation on HIV adaptation rates following vaccination.
- To assess the combined effects of risk compensation and viral adaptation on HIV epidemic control.
- To evaluate the long-term effectiveness of a partially effective HIV vaccine.
Main Methods:
- An agent-based epidemic model was utilized.
- The model was calibrated to HIV-1 trends in South Africa.
- Demographics, sexual network structure, behavior, and within-host dynamics were incorporated.
Main Results:
- Risk compensation was predicted to increase the rate of HIV viral adaptation.
- Combined risk compensation and viral adaptation can negate initial prevalence declines from vaccination.
- HIV prevalence at 15 years could equal or exceed levels seen without vaccination under certain scenarios.
Conclusions:
- Behavioral risk compensation can accelerate HIV evolution in response to vaccination.
- The interplay of risk compensation and viral adaptation may compromise vaccine-mediated epidemic control.
- Long-term HIV vaccine efficacy may be limited by evolutionary and behavioral factors.
Related Concept Videos
Retrovirus Life Cycles
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Viral Mutations
Vaccinations

